Moderna Inc. generates $ 12.2 billion in profits
On Friday Moderna Inc. Published its financial report for the year ending 31.12.2021. Report showed that Moderna’s total revenue was $ 18.471 billion which represents a staggering increase of 2.200%.
Of course, this is not surprising given that Moderna was one of the companies that received the authorization to research and develop the covid-19 vaccine. Since receiving approval to distribute the vaccine in 2020, Moderna has sold 824 million doses of the vaccine of which about 807 million were sold during 2021.
Moderna has sold 332 million doses of the vaccine to the US government, while 475 million doses to other governments around the world. Of these, it generated $ 17.7 billion in revenue. This means that its sales have increased 8,738 times compared to 2020 when the amount of money that Moderna had raised from the sale of vaccines was only 200 million euros.
In addition, Moderna has provided 6.7 billion deferred revenues (an advance it has received from its clients) that it is expected to realize during 2022.
Moderna Inc, Income statement as at 31.12
|
2021 |
2020 | Change |
% |
|
| Total revenue |
18,471 |
803 | 17,668 | 2200% |
| Total operating expenses |
5,175 |
1,566 | 3,609 |
230% |
| Income (loss) from operations |
13,296 |
(763) | 14,059 |
1843% |
| Interest income (expense) net |
(11) |
(30) | (7) |
-23% |
| Income (loss) before income taxes |
13,285 |
(744) | 14,029 |
1886% |
| Provision for income taxes |
1,083 |
3 |
1,080 |
36000% |
| Net income (loss) |
12,202 |
(747) | 12,949 |
1733% |
Despite the high level of current revenues and the promising future, Moderna’s stock price is constantly falling. The day it published the financial report the share price was $ 151.33 which is lower by $ 4.90 or 3.14%.
Moderna Inc. stock price year to date
